A BILL 
To establish the Advanced Research Projects Agency–Health, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Advanced Research 
4
Project Agency–Health Act’’ or the ‘‘ARPA–H Act’’. 
5
SEC. 
2. 
ADVANCED 
RESEARCH 
PROJECTS 
AGENCY– 
6
HEALTH. 
7
Title IV of the Public Health Service Act (42 U.S.C. 
8
281 et seq.) is amended by adding at the end the fol-
9
lowing: 
10
02:16 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
2 
•HR 5585 IH
‘‘PART J—ADVANCED RESEARCH PROJECTS 
1
AGENCY–HEALTH 
2
‘‘SEC. 499A. ADVANCED RESEARCH PROJECTS AGENCY– 
3
HEALTH. 
4
‘‘(a) ESTABLISHMENT.—There is established the Ad-
5
vanced Research Projects Agency–Health (in this part re-
6
ferred to as ‘ARPA–H’) within the Department of Health 
7
and Human Services. 
8
‘‘(b) GOALS AND ACTIVITIES.— 
9
‘‘(1) GOALS.—The goals of ARPA–H shall be 
10
to— 
11
‘‘(A) foster the development of new, break-
12
through capabilities, technologies, systems, and 
13
platforms to accelerate innovations in health 
14
and medicine; 
15
‘‘(B) revolutionize diagnosis, mitigation, 
16
prevention, and treatment of diseases through 
17
the development of transformative health tech-
18
nologies and high-need cures; 
19
‘‘(C) promote high-risk, high-reward inno-
20
vation to develop high-need cures; and 
21
‘‘(D) ensure the United States main-
22
tains— 
23
‘‘(i) global leadership in science and 
24
innovation; and 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
3 
•HR 5585 IH
‘‘(ii) the highest quality of life and 
1
health for its citizens. 
2
‘‘(2) MEANS.—ARPA–H shall achieve the goals 
3
under paragraph (1) by— 
4
‘‘(A) identifying and promoting revolu-
5
tionary advances in health sciences; 
6
‘‘(B) translating scientific discoveries into 
7
technological innovations and high-need cures; 
8
‘‘(C) providing resources and support to 
9
create platform capabilities that draw on mul-
10
tiple disciplines; 
11
‘‘(D) delivering advanced proofs of concept 
12
that demonstrate clinically meaningful ad-
13
vances; 
14
‘‘(E) accelerating transformational techno-
15
logical advances in areas with limited funding 
16
or technical certainty; and 
17
‘‘(F) prioritizing investments based on 
18
such considerations as— 
19
‘‘(i) scientific opportunity and unique-
20
ness of fit to the strategies and operating 
21
practices of ARPA–H; 
22
‘‘(ii) the effect on disease burden, in-
23
cluding unmet patient need and the fiscal 
24
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
4 
•HR 5585 IH
liability of the Federal Government with 
1
respect to health care; and 
2
‘‘(iii) potential opportunities to ad-
3
vance health equity. 
4
‘‘(c) DIRECTOR.— 
5
‘‘(1) IN
GENERAL.—The President shall ap-
6
point in the Department of Health and Human 
7
Services a director of ARPA–H (in this section re-
8
ferred to as the ‘Director’). 
9
‘‘(2) QUALIFICATIONS.—The Director shall be 
10
an individual who, by reason of professional back-
11
ground and experience, is especially qualified to 
12
manage— 
13
‘‘(A) research and advanced development 
14
programs; and 
15
‘‘(B) large-scale, high-risk initiatives with 
16
respect to health research across multiple sec-
17
tors, including generating high-need cures. 
18
‘‘(3) RELATIONSHIP TO SECRETARY.—The Di-
19
rector shall report to the Secretary. 
20
‘‘(4) DUTIES.—The duties of the Director shall 
21
include the following: 
22
‘‘(A) Approve and terminate the projects 
23
and programs of ARPA–H. 
24
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
5 
•HR 5585 IH
‘‘(B) Set research and development prior-
1
ities with respect to the goals under subsection 
2
(b) and manage the budget of ARPA–H. 
3
‘‘(C) Develop funding criteria and assess 
4
the success of programs through the establish-
5
ment of technical milestones. 
6
‘‘(D) Advance the goals under subsection 
7
(b), through consideration of the advice of the 
8
ARPA–H Interagency Advisory Committee es-
9
tablished under subsection (l). 
10
‘‘(E) Solicit data, as needed, from the Na-
11
tional Institutes of Health and other relevant 
12
Federal agencies, private entities, academia, 
13
nonprofit organizations, and international orga-
14
nizations. 
15
‘‘(F) Coordinate with the Director of the 
16
National Institutes of Health to ensure that the 
17
programs of ARPA–H build on and are in-
18
formed by scientific research supported by the 
19
National Institutes of Health. 
20
‘‘(G) Coordinate with the heads of Federal 
21
agencies and, to the extent practicable, ensure 
22
that the activities of ARPA–H supplement (and 
23
do not supplant) the efforts of other Federal 
24
agencies. 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
6 
•HR 5585 IH
‘‘(5) TERM.—The Director— 
1
‘‘(A) shall be appointed for a 5-year term; 
2
and 
3
‘‘(B) may be reappointed for 1 consecutive 
4
term. 
5
‘‘(6) AUTONOMY OF AGENCY REGARDING REC-
6
OMMENDATIONS
AND
TESTIMONY.—No officer or 
7
agency of the United States shall have any authority 
8
to require the Director or any other officer of 
9
ARPA–H to submit legislative recommendations, or 
10
testimony or comments on legislation, to any officer 
11
or agency of the United States for approval, com-
12
ments, or review prior to the submission of such rec-
13
ommendations, testimony, or comments to the Con-
14
gress, if such recommendations, testimony, or com-
15
ments to the Congress include a statement indi-
16
cating that the views expressed therein are those of 
17
the Director or such officer, and do not necessarily 
18
reflect the views of the President or another agency. 
19
‘‘(7) DELEGATION OF AUTHORITY.—The Direc-
20
tor may delegate to any duly authorized employee, 
21
representative, or agent any power vested in the Di-
22
rector or ARPA–H by law, except that the Director 
23
may not delegate the power to appoint the Deputy 
24
Director under paragraph (8). 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
7 
•HR 5585 IH
‘‘(8) DEPUTY DIRECTOR.—The Director shall 
1
appoint a deputy director to serve as acting Director 
2
in the absence or unavailability of the Director (not-
3
withstanding section 3345 of title 5, United States 
4
Code). 
5
‘‘(d) APPLICATION
OF
PAPERWORK
REDUCTION 
6
ACT.—The Director may waive the requirements of sub-
7
chapter I of chapter 35 of title 44, United States Code 
8
(commonly referred to as the ‘Paperwork Reduction Act’) 
9
with respect to the activities described under subsection 
10
(c)(3)(F). 
11
‘‘(e) PARTNERSHIPS.—In carrying out this section, 
12
the Director may partner with public and private entities, 
13
including— 
14
‘‘(1) other Federal agencies; 
15
‘‘(2) institutions of higher education; 
16
‘‘(3) private or public research institutions; 
17
‘‘(4) federally funded research and development 
18
centers; 
19
‘‘(5) private entities, including biotechnology, 
20
and pharmaceutical, medical device, and other health 
21
entities; and 
22
‘‘(6) nonprofit organizations, including patient 
23
advocacy groups. 
24
02:16 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
8 
•HR 5585 IH
‘‘(f) COORDINATION ON HIGH-NEED CURES.—The 
1
Director shall coordinate with the Commissioner of Food 
2
and Drugs and the Administrator of the Centers for Medi-
3
care & Medicaid Services to expedite the development, ap-
4
plication, coverage, and implementation of high-need 
5
cures. 
6
‘‘(g) AWARDS.—In carrying out this section, the Di-
7
rector may make awards in the form of grants, contracts, 
8
cooperative agreements, prizes, and other transactions, in-
9
cluding— 
10
‘‘(1) grants and cooperative agreements subject 
11
to the uniform administrative requirements, cost 
12
principles, and audit requirements for Federal 
13
awards contained in part 200 of title 2 of the Code 
14
of Federal Regulations; 
15
‘‘(2) contracts subject to chapter 1 of title 48, 
16
Code of Federal Regulations (or successor regula-
17
tions) (commonly referred to as the ‘Federal Acqui-
18
sition Regulation’) but exempt from the regulations 
19
specified in chapter 3 of title 48, Code of Federal 
20
Regulations (or successor regulations); 
21
‘‘(3) multi-year contracts under section 3903 of 
22
title 41, United States Code; 
23
‘‘(4) prize competitions; and 
24
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
9 
•HR 5585 IH
‘‘(5) other transactions or prototype projects 
1
that are directly relevant to enhancing such goals. 
2
‘‘(h) FACILITIES AUTHORITY.—The Director may— 
3
‘‘(1) acquire (by purchase, lease, condemnation 
4
or otherwise), construct, improve, repair, operate, 
5
and maintain such real and personal property nec-
6
essary to carry out this section; and 
7
‘‘(2) lease an interest in property for not more 
8
than 20 years, notwithstanding section 1341(a)(1) 
9
of title 31, United States Code. 
10
‘‘(i) PERSONNEL.— 
11
‘‘(1) IN GENERAL.—The Director of ARPA–H 
12
shall have the authority to— 
13
‘‘(A) hire personnel under section 207(f) 
14
and establish governing criteria to recruit, ap-
15
point, and compensate personnel under this sec-
16
tion without regard to any provision in title 5, 
17
United States Code, governing appointments 
18
under the civil service laws and fix the com-
19
pensation of such personnel at a rate to be de-
20
termined by the Director, up to the amount of 
21
annual compensation (excluding expenses) spec-
22
ified in section 102 of title 3, United States 
23
Code, notwithstanding section 202 of the De-
24
partment of Health and Human Services Ap-
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
10 
•HR 5585 IH
propriations Act, 1993 (Public Law 102–394) 
1
or any provision of title 5, United States Code, 
2
governing the rates of pay or classification of 
3
employees in the executive branch; 
4
‘‘(B) make additional appointments of sci-
5
entific, medical, and professional personnel 
6
under this section without regard to any provi-
7
sion in title 5, United States Code, governing 
8
appointments under the civil service laws and 
9
fix the compensation of such personnel at a rate 
10
to be determined by the Director, up to the 
11
amount of annual compensation (excluding ex-
12
penses) specified in section 102 of title 3, 
13
United States Code, notwithstanding section 
14
202 of Department of Health and Human Serv-
15
ices Appropriations Act, 1993 (Public Law 
16
102–394) or any provision of title 5, United 
17
States Code, governing the rates of pay or clas-
18
sification of employees in the executive branch; 
19
and 
20
‘‘(C) make appointments to positions of 
21
administration or management of ARPA–H 
22
without regard to any provision in title 5, 
23
United States Code, governing appointments 
24
under the civil service laws and fix the com-
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
11 
•HR 5585 IH
pensation of such personnel at a rate to be de-
1
termined by the Director, up to the amount of 
2
annual compensation (excluding expenses) spec-
3
ified in section 102 of title 3, United States 
4
Code, notwithstanding section 202 of Depart-
5
ment of Health and Human Services Appro-
6
priations Act, 1993 (Public Law 102–394) or 
7
any provision of title 5, United States Code, 
8
governing the rates of pay or classification of 
9
employees in the executive branch. 
10
‘‘(2) ADDITIONAL
STAFF.—The Director of 
11
ARPA–H may use all authorities in existence on the 
12
date of enactment of this section that are provided 
13
to the Secretary to hire administrative, financial, 
14
legal, contracts, legislative affairs, and information 
15
technology staff, and such other staff as may be 
16
identified by the Director as necessary to carry out 
17
this section. 
18
‘‘(3) ADDITIONAL
CONSIDERATIONS.—In ap-
19
pointing qualified personnel under this subsection, 
20
the Director— 
21
‘‘(A) may contract with private entities; 
22
and 
23
‘‘(B) shall make efforts to recruit and re-
24
tain a diverse workforce, including individuals 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
12 
•HR 5585 IH
underrepresented in science and medicine and 
1
racial and ethnic minorities. 
2
‘‘(4) ADDITIONAL HIRING AUTHORITY.—To the 
3
extent needed to carry out the duties in paragraph 
4
(1), the Director is authorized to utilize hiring au-
5
thorities under section 3372 of title 5, United States 
6
Code, to staff ARPA–H with employees from other 
7
Federal agencies, State and local governments, In-
8
dian Tribes and Tribal organizations, institutions of 
9
higher education, and other organizations, as de-
10
scribed in that section, in the same manner and sub-
11
ject to the same conditions, that apply to such indi-
12
viduals utilized to accomplish other purposes. 
13
‘‘(5) EXISTING AUTHORITIES.—The authorities 
14
granted by this section are— 
15
‘‘(A) in addition to existing authorities 
16
granted to the Secretary; and 
17
‘‘(B) are not intended to supersede or 
18
modify any existing authorities. 
19
‘‘(j) PROGRAM MANAGERS.— 
20
‘‘(1) IN
GENERAL.—The Director shall des-
21
ignate employees of ARPA–H to serve as program 
22
managers for the programs carried out by ARPA– 
23
H. 
24
‘‘(2) DUTIES.—A program manager shall— 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
13 
•HR 5585 IH
‘‘(A) establish research and development 
1
goals for programs in accordance with guidance 
2
from the Director; 
3
‘‘(B) collaborate with experts from the Na-
4
tional Institutes of Health and other Federal 
5
agencies and experts in relevant scientific fields 
6
to identify research and development opportuni-
7
ties; 
8
‘‘(C) convene workshops, as needed, with 
9
relevant Federal agencies, institutions of higher 
10
education, nonprofit research institutions, com-
11
panies, venture capital firms, and nonprofit or-
12
ganizations for the development of high-need 
13
cures; 
14
‘‘(D) issue funding opportunity announce-
15
ments; 
16
‘‘(E) select, on the basis of merit, each of 
17
the projects to be supported under a program 
18
carried out by ARPA–H, taking into consider-
19
ation— 
20
‘‘(i) the novelty and scientific and 
21
technical merit of the proposed projects; 
22
‘‘(ii) the demonstrated capabilities of 
23
the applicants to successfully carry out the 
24
proposed project; 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
14 
•HR 5585 IH
‘‘(iii) the unmet needs within patient 
1
populations; 
2
‘‘(iv) the consideration by the appli-
3
cant of future commercial applications of 
4
the project, including the feasibility of 
5
partnering with one or more commercial 
6
entities; and 
7
‘‘(v) such other criteria as are estab-
8
lished by the Director; 
9
‘‘(F) identify milestones and monitor 
10
progress of such milestones with respect to each 
11
project; 
12
‘‘(G) provide recommendations to the Di-
13
rector with respect to advancing the goals 
14
under subsection (b); 
15
‘‘(H) identify opportunities for the com-
16
mercial application of successful projects, in-
17
cluding through the establishment of partner-
18
ships between or among awardees; and 
19
‘‘(I) provide recommendations to expand, 
20
restructure, or terminate research partnerships 
21
or projects. 
22
‘‘(3) TERM.—A program manager may serve 
23
not greater than 2 terms for a period of 3 years 
24
each. 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
15 
•HR 5585 IH
‘‘(k) REPORTS AND EVALUATION.— 
1
‘‘(1) ANNUAL REPORT.— 
2
‘‘(A) IN
GENERAL.—Beginning not later 
3
than 1 year after the date of the enactment of 
4
this section, and each fiscal year thereafter, the 
5
Director shall submit a report on the actions 
6
undertaken, and results generated, by ARPA– 
7
H, including— 
8
‘‘(i) a description of projects sup-
9
ported by ARPA–H in the previous fiscal 
10
year and whether such projects are meet-
11
ing the goals developed by the Director 
12
pursuant to subsection (c)(4)(C); 
13
‘‘(ii) a description of projects termi-
14
nated in the previous fiscal year, and the 
15
reason for such termination; 
16
‘‘(iii) a description of projects starting 
17
in the next fiscal year, as available; 
18
‘‘(iv) activities conducted in coordina-
19
tion with other Federal agencies; and 
20
‘‘(v) an analysis of the extent of co-
21
ordination conducted pursuant to sub-
22
sections (c)(4)(F) and (f), including suc-
23
cesses and barriers with respect to achiev-
24
ing the goals under subsection (b). 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
16 
•HR 5585 IH
‘‘(B) SUBMISSION TO CONGRESS.—The re-
1
port under subsection (a) shall be submitted 
2
to— 
3
‘‘(i) the Committee on Energy and 
4
Commerce and the Committee on Appro-
5
priations of the House of Representatives; 
6
and 
7
‘‘(ii) the Committee on Health, Edu-
8
cation, Labor, and Pensions and the Com-
9
mittee on Appropriations of the Senate. 
10
‘‘(2) EVALUATION.— 
11
‘‘(A) IN GENERAL.—Not later than 8 years 
12
after the date of the enactment of this section, 
13
the Secretary shall enter into an agreement 
14
with the National Academies of Sciences, Engi-
15
neering, and Medicine to study and evaluate 
16
whether ARPA–H has met the goals under sub-
17
section (b). 
18
‘‘(B) 
SUBMISSION
OF
RESULTS.—The 
19
agreement entered into under subparagraph (A) 
20
shall require the National Academies of 
21
Sciences, Engineering, and Medicine to submit 
22
the results of the evaluation conducted under 
23
such agreement to the Secretary, the Com-
24
mittee on Energy and Commerce of the House 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
17 
•HR 5585 IH
of Representatives and the Committee on 
1
Health, Education, Labor, and Pensions of the 
2
Senate. 
3
‘‘(l) STRATEGIC PLAN.—Not later than 1 year after 
4
the date of the enactment of this section, and every 4 
5
years thereafter, the Director shall provide to the relevant 
6
committees of Congress a strategic plan describing how 
7
ARPA–H will carry out investments each fiscal year in 
8
the next 4-year period. 
9
‘‘(m) ADDITIONAL ADVICE.—In carrying out this sec-
10
tion, the Director may seek advice from— 
11
‘‘(1) the President’s Committee of Advisors on 
12
Science and Technology; 
13
‘‘(2) peers in the scientific community, includ-
14
ing academia and industry; 
15
‘‘(3) experts in other Federal agencies; 
16
‘‘(4) any professional or scientific organization 
17
with expertise technologies under development by 
18
ARPA–H or a relevant scientific discipline; and 
19
‘‘(5) representatives of patient communities. 
20
‘‘(n) ARPA–H ADVISORY COMMITTEE.— 
21
‘‘(1) IN GENERAL.—The Director shall establish 
22
an interagency advisory committee to be known as 
23
the ARPA–H Interagency Advisory Committee (re-
24
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
18 
•HR 5585 IH
ferred to in this subsection as the ‘Advisory Com-
1
mittee’). 
2
‘‘(2) MEMBERSHIP.—The Advisory Committee 
3
may include any or all of the following members, or 
4
designees: 
5
‘‘(A) The Director of the National Insti-
6
tutes of Health. 
7
‘‘(B) The Director of National Center for 
8
Advancing Translational Sciences. 
9
‘‘(C) The Director of Office of Science and 
10
Technology Policy. 
11
‘‘(D) The Commissioner of the Food and 
12
Drug Administration. 
13
‘‘(E) The Director of the Biomedical Ad-
14
vanced Research and Development Authority. 
15
‘‘(F) The Director of the Centers for Dis-
16
ease Control and Prevention. 
17
‘‘(G) The Administrator of the Centers for 
18
Medicare & Medicaid Services. 
19
‘‘(H) The Director of the Agency for 
20
Healthcare Research and Quality. 
21
‘‘(I) The Director of the Office of Minority 
22
Health. 
23
‘‘(J) The Administrator of the Health Re-
24
sources and Services Administration. 
25
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
19 
•HR 5585 IH
‘‘(K) The Director of the Defense Ad-
1
vanced Research Projects Agency. 
2
‘‘(L) The Director of the National Science 
3
Foundation. 
4
‘‘(M) The Director of the Office of Science 
5
of the Department of Energy. 
6
‘‘(N) Representatives of any Federal agen-
7
cy with subject matter expertise that the Direc-
8
tor of ARPA–H determines is necessary for the 
9
successful completion of a project carried out 
10
pursuant to this section. 
11
‘‘(3) DUTIES.—The Advisory Committee shall 
12
advise the Director, including by— 
13
‘‘(A) making recommendations on— 
14
‘‘(i) research priorities that will pro-
15
vide the greatest return on investment with 
16
respect to improving human health; 
17
‘‘(ii) avoiding duplication of efforts in 
18
the Federal Government; and 
19
‘‘(iii) improving coordination with 
20
other Federal agencies; and 
21
‘‘(B) identifying and developing strategies 
22
to address market barriers to commercialization 
23
or adoption of high-need cures. 
24
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
20 
•HR 5585 IH
‘‘(4) NON-APPLICABILITY OF FACA.—The Fed-
1
eral Advisory Committee Act (5 U.S.C. App.) shall 
2
not apply to the Advisory Committee. 
3
‘‘(5) ADVISORY NATURE.—The function of the 
4
Committee shall be advisory in nature. Nothing in 
5
this section shall be construed as giving the Com-
6
mittee authority over the activities authorized under 
7
this section. 
8
‘‘(o) RULE
OF CONSTRUCTION.—The authorities 
9
under this section, with respect to the Director, are addi-
10
tional authorities that do not supersede or modify any ex-
11
isting authorities. 
12
‘‘(p) DEFINITIONS.—In this section: 
13
‘‘(1) ADVANCED
PROOFS
OF
CONCEPT.—The 
14
term ‘advanced proofs of concept’ means data, a 
15
prototype, or other experimental evidence that— 
16
‘‘(A) may precede the development of a 
17
high-need cure or health technology; and 
18
‘‘(B) demonstrates the feasibility of a new 
19
concept. 
20
‘‘(2) BIOLOGICAL
PRODUCT.—The term ‘bio-
21
logical product’ has the meaning given such term in 
22
section 262 of the Federal Food, Drug, and Cos-
23
metic Act. 
24
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
21 
•HR 5585 IH
‘‘(3) DRUG.—The term ‘drug’ has the meaning 
1
given such term in section 201 of the Federal Food, 
2
Drug, and Cosmetic Act. 
3
‘‘(4) DEVICE.—The term ‘device’ has the mean-
4
ing given such term in section 201 of the Federal 
5
Food, Drug, and Cosmetic Act. 
6
‘‘(5) FEDERAL
ACQUISITION
REGULATION.— 
7
The term ‘Federal Acquisition Regulation’ means 
8
the Federal Acquisition Regulation issued pursuant 
9
to section 1303(a)(1) of title 41, United States 
10
Code. 
11
‘‘(6) HIGH-NEED CURE.—The term ‘high-need 
12
cure’ means a drug, biological product, or device— 
13
‘‘(A) that should be prioritized to detect, 
14
diagnose, mitigate, prevent, or treat any disease 
15
or medical condition; and 
16
‘‘(B) for which incentives in commercial 
17
market are unlikely to result in the adequate or 
18
timely development of such drug, biological 
19
product, or device. 
20
‘‘(7) PRIZE
COMPETITIONS.—The term ‘prize 
21
competitions’ has the meaning given such term in 
22
section 24 of the Stevenson-Wydler Technology In-
23
novation Act of 1980 (15 U.S.C. 3719). 
24
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
22 
•HR 5585 IH
‘‘SEC. 499B. HEALTH ADVANCED RESEARCH AND DEVELOP-
1
MENT FUND. 
2
‘‘(a) ESTABLISHMENT.—There is established in the 
3
Treasury a fund to be known as the Health Advanced Re-
4
search and Development Fund (in this section referred to 
5
as the ‘Fund’) which shall be administered by the Director 
6
of ARPA–H for the purposes of carrying out section 
7
499A. 
8
‘‘(b) SEPARATE BUDGET REQUEST.—The annual 
9
budget request for ARPA–H shall be separate from the 
10
rest of the budget for the Department of Health and 
11
Human Services. The Director of ARPA–H shall prepare 
12
and submit directly to the President for review and trans-
13
mittal to Congress, an annual budget for ARPA–H after 
14
reasonable opportunity for comment (but without change) 
15
by the Secretary. 
16
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.— 
17
‘‘(1) IN GENERAL.—There are authorized to be 
18
appropriated to the Fund, $3,000,000,000 for fiscal 
19
year 2022, to remain available until expended. 
20
‘‘(2) ADVANCE APPROPRIATIONS.—For each fis-
21
cal year beginning with fiscal year 2022, discre-
22
tionary new budget authority provided in an appro-
23
priations Act for ARPA–H shall— 
24
‘‘(A) be made available for that fiscal year; 
25
and 
26
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
23 
•HR 5585 IH
‘‘(B) include advance discretionary new 
1
budget authority that first becomes available 
2
for the first fiscal year following the budget 
3
year. 
4
‘‘(3) SEPARATE APPROPRIATIONS.—Appropria-
5
tions to the Fund shall be separate and distinct 
6
from other appropriations for the Department.’’. 
7
Æ 
01:12 Oct 16, 2021
H5585
ctelli on DSK11ZRN23PROD with BILLS
